NPPB and breast carcinoma: This phenomenon is seen in breast cancer patients exposed to other cardiotoxic agents such as trastuzumab, which has been shown to cause a higher risk of developing cardiotoxicity in patients whose NT-proBNP levels were above the upper limit of the normal range.